MDGEF (Medigene AG) Inventories, Other : $0.00 Mil (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Medigene AG Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Medigene AG's other inventories for the quarter that ended in Jun. 2024 was $0.00 Mil.

Medigene AG Inventories, Other Historical Data

The historical data trend for Medigene AG's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Inventories, Other Chart

Medigene AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Other

Get a 7-Day Free Trial

Medigene AG Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Inventories, Other	Get a 7-Day Free Trial															-	-	-	-	-

Medigene AG Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Medigene AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (OTCPK:MDGEF) » Definitions » Inventories, Other

Comparable Companies

Traded in Other Exchanges

0QGJ:UK MDG1:Germany

Address

Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.